© 2024 HSP News Service, L.L.C.
In a long-term follow-up of Women’s Health Initiative (WHI) randomized trials reported in the Journal of Clinical Oncology, Rowan T. Chlebowski, MD, PhD, and colleagues identified risks of ovarian and endometrial cancers associated with the use of menopausal hormone therapy. Study Details The...
The rate of human papillomavirus (HPV) vaccination may be lower among female individuals with mental health issues or neurodevelopmental conditions compared with their peers, according to a recent study published by Hu et al in The Lancet Public Health. Background The HPV vaccine is capable of...
Researchers may have uncovered the germline mutational landscape of Chinese patients with ovarian cancer and identified an enriched RAD51D variant in these patients, according to a recent study published by Feng et al in JCO Global Oncology. The findings could serve as a critical reference for...
Endometrial cancer is most frequently diagnosed among women aged 55 to 65, with a median age at diagnosis of 64 years.1 In epidemiologic studies, women diagnosed with endometrial cancer at an older age are more likely to have high-grade disease, aggressive histology, deep myometrial invasion, lower ...
In a systemic analysis of global literature reported in The Lancet, Wei et al estimated the proportion of invasive cervical cancer cases caused by specific human papillomavirus (HPV) genotypes. Study Details A literature search through February 2024 was performed to identify studies reporting HPV...
Researchers have discovered that uterine serous carcinoma tumors in Black patients tend to express more aggressive and immunosuppressive features than tumors in White patients, according to a recent study published by Foley et al in Proceedings of the National Academy of Sciences. Uterine serous...
As reported in The Lancet Oncology by Nicoletta Colombo, MD, and colleagues, the phase III AtTEnd trial showed improved progression-free survival with the addition of atezolizumab to chemotherapy in patients with recurrent or advanced endometrial cancer, particularly among those with mismatch...
“Symptom-triggered testing”—prompted by symptoms such as pain, abdominal bloating/swelling, and feeling full soon after starting to eat—detected early-stage aggressive ovarian cancer in one of four individuals affected, according to an analysis from the ROCkeTS trial published by Kwong et al in the ...
Women whose fallopian tubes are removed during sterilization via laparoscopy may have only marginally more surgical complications compared with those whose tubes are cut during tubal occlusion, according to a recent study published by Strandell et al in The Lancet Regional Health–Europe. The...
Cancer screening may cost more than $40 billion annually in the United States, according to a recent study published by Halpern et al in the Annals of Internal Medicine. Study Methods and Results In the recent modeling study, investigators used national health-care survey and cost resources data to ...
In a population-based retrospective cohort study (Teenage and Young Adult Cancer Survivor Study; TYACSS) reported in The Lancet Oncology, Sunguc et al identified risks of adverse obstetric outcomes among female survivors of adolescent and young adult cancers in England and Wales. Study Details The...
As reported in the Journal of Clinical Oncology by Alessandro D. Santin, MD, and colleagues, findings in the endometrial cancer cohort of the phase II multicohort TROPiCS-03 trial indicated activity of the Trop-2–directed antibody-drug conjugate sacituzumab govitecan-hziy in pretreated patients...
The results of routine blood tests could be used to speed up cancer diagnoses among patients with abdominal symptoms, according to a recent study published by Rafiq et al in PLOS Medicine. Background Most patients who report symptoms of abdominal pain or bloating to their physicians are referred...
On August 1, the U.S. Food and Drug Administration (FDA) approved dostarlimab-gxly (Jemperli) with carboplatin and paclitaxel, followed by single-agent dostarlimab, for adults with primary advanced or recurrent endometrial cancer. Dostarlimab was previously approved in July 2023 with carboplatin...
I first met Lyn Denny, MD, PhD, in Ghana, in 2004, when she became the Secretary Treasurer of AORTIC and brought the organization back to life. We’ve been friends ever since. I equate Lyn’s unwavering dedication to bringing health equity to women in Africa to Nelson Mandela’s fight for social...
The global oncology and public health communities are mourning the death of Lynette Ann Denny, MD, PhD, a world-renowned gynecologic oncologist and a leading researcher in the prevention of cervical cancer in low-resource settings. Dr. Denny died on June 9, 2024, in Cape Town, South Africa, of...
Patients with BRCA1- or BRCA2-mutated ovarian cancer may have a lower risk of developing breast cancer following treatment, according to a recent study published by Evans et al in Genetics in Medicine. Background Previous research has estimated that the risk of developing breast cancer by the age...
Some patients with a genetic predisposition for cancer may not qualify for genetic screenings under the current guidelines, according to a recent study published by Samadder et al in JCO Precision Oncology. Researchers are investigating how to advance personalized medicine and tailor prevention and ...
In a Utah population–based cohort study reported in JAMA Network Open, Barnard et al found that women with ovarian endometriomas and/or deep-infiltrating endometriosis had a markedly increased risk of developing ovarian cancer. Those with such severe subtypes may represent an important population...
As reported in The New England Journal of Medicine by Ignace Vergote, MD, PhD, and colleagues, interim analysis of the phase III innovaTV 301 trial has shown improved overall survival and other efficacy outcomes with the antibody-drug conjugate tisotumab vedotin-tftv vs investigator’s choice of...
In a study reported in JAMA Oncology, Kemi Doll, MD, MSCR, and colleagues found that ultrasonography-measured endometrial thickness was not reliable in triage for diagnosing endometrial cancer among Black women. Study Details The retrospective U.S. multicenter study focused on data from 1,494 women ...
Investigators found that more than 50% of health-care providers surveyed might offer human papillomavirus (HPV) self-collection testing to their patients if the U.S. Food and Drug Administration (FDA) approved the procedure, according to a recent study published by Fontenot et al in Women’s Health...
In an English and Welsh study (The Teenage and Young Adult Cancer Survivor Study) reported in The Lancet Oncology, Sunguc et al found that cervical cancer and leukemia survivors have a heightened risk of experiencing several serious obstetric complications. “Therefore, any pregnancy [in these...
In 2002, the federally funded Women’s Health Initiative (WHI),1 a randomized, placebo-controlled clinical trial investigating menopausal hormone therapy for healthy menopausal women, was abruptly halted when it was determined that taking estrogen and progestin hormones after menopause increased the ...
Adding retroperitoneal lymphadenectomy to cytoreductive surgery during primary debulking surgery or interval cytoreductive surgery after neoadjuvant chemotherapy failed to improve progression-free or overall survival in patients with advanced ovarian cancer who have no suspicious nodes, according...
On March 22, 2024, mirvetuximab soravtansine-gynx (Elahere) was granted regular approval for adult patients with folate receptor–alpha (FRα)-positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received one to three prior systemic treatment...
Investigators uncovered crucial insights into the cancer screening behaviors of a population of Muslim individuals residing in the Washington, DC, metropolitan area that could help illuminate the influence of cultural and religious beliefs on health practices, according to a recent study published...
On June 17, the U.S. Food and Drug Administration (FDA) approved pembrolizumab (Keytruda) in combination with carboplatin and paclitaxel followed by single-agent pembrolizumab for adult patients with primary advanced or recurrent endometrial carcinoma; on June 14, the agency approved durvalumab...
This is Part 3 of Overcoming Platinum Resistance in Ovarian Cancer: New Strategies and Novel Targets, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, Drs. Kathleen Moore, Katherine Fuh, and Bhavana Pothuri discuss the treatment of advanced ovarian cancer after progression on both platinum-based therapy and a PARP inhibitor. The patient is a 72-year-old woman with a history of stage IIIC high-grade serous ovarian cancer diagnosed in 2019. Molecular profiling revealed that she is BRCA wild-type and HRD-positive. She was treated with neoadjuvant paclitaxel and carboplatin plus bevacizumab, followed by bevacizumab maintenance for 1 year. Twenty-four months after her last platinum-based therapy, she experienced disease recurrence with liver metastases. At the time of her recurrence, she was treated with carboplatin and pegylated liposomal doxorubicin for six cycles and had a partial response. She was then treated with maintenance olaparib for 12 months, experienced disease progression, and returned to carboplatin monotherapy. Unfortunately, after four cycles of carboplatin, her disease progressed again. In the conversation that follows, the faculty discuss whether prior progression on a PARP inhibitor and platinum-based therapy influence their choice of therapy in the platinum-resistant setting, the role of HER2-targeting antibody-drug conjugates, and the importance of next-generation sequencing and testing for immunohistochemistry to better match patients to clinical trials.
This is Part 2 of Overcoming Platinum Resistance in Ovarian Cancer: New Strategies and Novel Targets, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, Drs. Kathleen Moore, Katherine Fuh, and Bhavana Pothuri discuss the treatment of advanced ovarian cancer when progression of disease has occurred after platinum-based therapy. The patient is a 66-year-old woman with a history of stage IIIC high-grade serous ovarian cancer diagnosed in 2019. She was treated with primary cytoreductive surgery with no gross residual disease, followed by paclitaxel and carboplatin plus bevacizumab, and then bevacizumab maintenance for 1 year. She is BRCA wild-type and HRD-negative. Eighteen months after her last platinum, she experienced disease recurrence with abdominal disease and subsequently received carboplatin and pegylated liposomal doxorubicin plus bevacizumab for six cycles, achieving a partial response. Unfortunately, 5 months after her last platinum, she experienced disease recurrence again, with liver metastases and moderate ascites. In the conversation that follows, the faculty discuss key biomarkers to look for when determining a patient’s treatment course, whether platinum-based therapy is ever warranted in the setting of platinum resistance, the role of folate receptor inhibitors, and new therapies on the horizon.
This is Part 1 of Overcoming Platinum Resistance in Ovarian Cancer: New Strategies and Novel Targets, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, Drs. Kathleen Moore, Katherine Fuh, and Bhavana Pothuri discuss the treatment of advanced ovarian cancer with disease progression on platinum-based therapy. The patient is a 75-year-old woman with a history of stage IV high-grade endometrioid ovarian cancer diagnosed in 2020. She is BRCA wild-type. She was treated with neoadjuvant paclitaxel and carboplatin for three cycles and underwent successful interval cytoreductive surgery. She then received three additional cycles of paclitaxel and carboplatin and 1 year of niraparib maintenance, at which point she was found to have progressive disease. Following recurrence, she received carboplatin and pegylated liposomal doxorubicin plus bevacizumab for three cycles until her disease progressed again. She is now considered to be platinum-resistant. In the conversation that follows, the faculty discuss patient-specific considerations when choosing therapy for platinum-resistant ovarian cancer, the importance of obtaining tissue for thorough biomarker evaluation to assess eligibility for clinical trials, and current standard of care options.
The highly anticipated ENGOT-en9/LEAP-001 trial in endometrial cancer has missed both its primary endpoints. At the Society of Gynecologic Oncology (SGO) 2024 Annual Meeting on Women’s Cancer, the study investigators reported no significant benefit in progression-free survival or overall survival...
The risk of breast cancer and ovarian cancer may be increased in some women who experience early menopause, according to new findings presented by Welt et al at the Endocrine Society’s Annual Meeting & Exposition 2024. Primary ovarian insufficiency is a condition that occurs when a woman’s...
Yukio Suzuki, MD, PhD, of Columbia University College of Physicians and Surgeons, discusses data showing that reproductive-age patients with early-stage endometrial cancer who use fertility-preserving hormonal therapy seemed to have good overall survival after a 10-year follow-up (Abstract 5508).
Alex Andrea Francoeur, MD, of UC Irvine Health, discusses data showing an association between the increasing incidence of endometrial cancer and obesity, which disproportionately affects younger women and women of color. According to Dr. Francoeur, the findings warrant targeted health services and public health interventions to stabilize and ultimately reverse the rising rates (Abstract 5507).
Mostafa Eyada, MD, of The University of Texas MD Anderson Cancer Center, discusses study results showing that bevacizumab in combination with oral cyclophosphamide had a response rate of 40% in patients with recurrent platinum-resistant high-grade ovarian cancer (Abstract 5517).
Jean-Marc Classe, MD, PhD, of France’s Nantes Université, discusses phase III results showing that systematic lymphadenectomy should be omitted in patients with advanced epithelial ovarian cancer with clinically negative lymph nodes, as well as those undergoing neoadjuvant chemotherapy and interval complete surgery (LBA5505).
Some people with advanced epithelial ovarian cancer may safely avoid having their lymph nodes removed during surgery without it impacting their survival outcomes, helping to reduce the risk of postoperative complications. This research was presented by Classe et al at the 2024 ASCO Annual Meeting...
Don S. Dizon, MD, of Legorreta Cancer Center at Brown University and Lifespan Cancer Institute, discusses final phase II results of the BrUOG 354 trial showing that, for patients with ovarian and other extrarenal clear cell cancers, nivolumab and ipilimumab warrant further evaluation against standard treatment, given the historically chemotherapy-resistant nature of the disease (LBA5500).
Katherine C. Fuh, MD, PhD, of the University of California, San Francisco, discusses phase III findings of the AXLerate-OC trial, showing that batiraxcept with paclitaxel compared to paclitaxel alone improved progression-free and overall survival in patients with platinum-resistant recurrent ovarian cancer whose tumors were AXL-high in an exploratory analysis (LBA5515).
In a phase I/II NRG Oncology Group study reported in the Journal of Clinical Oncology, Landen et al found that the addition of ruxolitinib to front-line paclitaxel/carboplatin neoadjuvant chemotherapy and interval debulking surgery improved progression-free survival in patients with stage III to IV ...
In 2002, the federally funded Women’s Health Initiative—a randomized, placebo-controlled clinical trial investigating the effects of menopausal hormone therapy in healthy menopausal women—was abruptly halted when it was determined that taking estrogen and progestin hormones after menopause...
As reported in The New England Journal of Medicine by Marie Plante, MD, of Centre Hospitalier Universitaire de Quebec, and colleagues, the phase III CX.5 SHAPE trial has shown noninferiority of simple vs radical hysterectomy in the frequency of pelvic recurrence in women with low-risk cervical...
A longitudinal cohort study published by Gottschlich et al in Cancer Epidemiology, Biomarkers & Prevention investigated the optimal interval between screening tests and the long-term risk of cervical precancer or worse (CIN2+). Researchers found that the risk of cervical precancer 8 years after ...
The National Comprehensive Cancer Network® published its first set of Clinical Practice Guidelines in Oncology (NCCN Guidelines®) in 1996, covering eight tumor types. Currently, guidelines are available for more than 60 tumor types, subtypes, and related topics. The NCCN’s 29th Annual Conference...
On May 15, Roche announced the U.S. Food and Drug Administration (FDA) approval of its human papillomavirus (HPV) self-collection solution—one of the first of such tests available in the United States. Screening for HPV can help identify women who are at risk of developing cervical cancer so that...
In an analysis of data from the PORTEC-1, -2, and -3 trials reported in The Lancet Oncology, Wakkerman et al found that older age was associated with more aggressive tumor features and poorer outcomes in patients with endometrial cancer. Study Details The analysis included data from 1,801...
New research findings have highlighted the importance of personalized treatment approaches with the monoclonal antibody durvalumab based on mismatch repair (MMR) status in newly diagnosed patients with advanced or recurrent endometrial cancer, according to data presented during the Society of...
As reported in the Journal of Clinical Oncology by Ann H. Klopp, MD, PhD, and colleagues, results from an NRG Oncology/GOG trial showed “excellent” progression-free survival outcomes with radiation therapy alone for local recurrences of endometrial cancer, with the addition of cisplatin in...
In patients with ovarian cancer, second-look surgery may find a role again. The evaluation of measurable residual disease (MRD) using second-look laparoscopy identified more women who had detectable MRD after front-line treatment than did circulating tumor DNA (ctDNA), according to a study...